Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Balk At AMAG-Allos Proposed Marriage

This article was originally published in The Pink Sheet Daily

Executive Summary

An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
Advertisement

Related Content

Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger
Allos Looks To Boost Lymphoma Drug Folotyn's Prospects With Mundipharma Deal
AMAG Pharmaceuticals: Enough Irons In The Fire?
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn

Topics

Advertisement
UsernamePublicRestriction

Register

PS072540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel